BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study-Reference-Cited by-同舟云学术

BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study

Published:2022-07 Issue:7 Volume:17 Page:921-930
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Louw Amber,Panou Vasiliki,Szejniuk Weronika Maria,Meristoudis Christos,Chai Siaw Ming,van Vliet Chris,Lee Y. C. Gary,Dick Ian M.,Firth Tina,Lynggaard Louise Andersen,Asghari Azadeh Birbaneh,Vyberg Mogens,Hansen Johnni,Creaney Jenette,Røe Oluf Dimitri

Funder

NTNU

UWA

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic;Røe;Eur Respir Rev,2015

2. Loss of p16 expression is associated wtih histological features of melanomia invasion;Pavey;Melanoma Res,2002

3. Malignant mesothelioma;Robinson;Lancet,2005

4. BRCA-1 associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignancy pleural mesothelioma classification: a large retrospective study;Righi;J Thorac Oncol,2016

5. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?;Current Oncology;2024-08-27

2. Primary Intrahepatic Mesothelioma: Case Series and Systematic Review of Literature;Journal of Gastrointestinal Cancer;2024-08-14

3. Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling;Proceedings of the National Academy of Sciences;2024-07-11

4. BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma;JTO Clinical and Research Reports;2024-05

5. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis;Pathology - Research and Practice;2024-05